Evidence map›Paper›PMID 34371735›Full record

ReviewPharmaceutics2021

Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream.

Paul Smith, Wenqing Yao, Stacey Shepard, Maryanne Covington, Jim Lee, Jennifer Lofland, Ahmad Naim, Trupti Sheth, Bhavnish Parikh, Swamy Yeleswaram

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis.American journal of clinical dermatology · 2023
    Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Paul SmithIncyte Research Institute, 1801 Augustine Cut-Off, Wilmington, DE 19803, USA.
Wenqing YaoIncyte Corporation, 1801 Augustine Cut-Off, Wilmington, DE 19803, USA.
Stacey ShepardIncyte Research Institute, 1801 Augustine Cut-Off, Wilmington, DE 19803, USA.
Maryanne CovingtonIncyte Research Institute, 1801 Augustine Cut-Off, Wilmington, DE 19803, USA.
Jim LeeIncyte Corporation, 1801 Augustine Cut-Off, Wilmington, DE 19803, USA.
Jennifer LoflandIncyte Corporation, 1801 Augustine Cut-Off, Wilmington, DE 19803, USA.
Ahmad NaimIncyte Corporation, 1801 Augustine Cut-Off, Wilmington, DE 19803, USA.
Trupti ShethIncyte Corporation, 1801 Augustine Cut-Off, Wilmington, DE 19803, USA.
Bhavnish ParikhIncyte Corporation, 1801 Augustine Cut-Off, Wilmington, DE 19803, USA.
Swamy YeleswaramIncyte Research Institute, 1801 Augustine Cut-Off, Wilmington, DE 19803, USA.
Incyte (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Named after the two-faced Roman god of doorways, Janus kinases (JAKs) represent a class of tyrosine kinases. The JAK signaling pathway is pivotal for the downstream signaling of inflammatory cytokines, including interleukins, interferons, and multiple growth factors. This article provides an overview of the JAK pathway and signaling, its significance in immune-mediated dermatologic diseases and the development of a targeted, localized option of a selective JAK inhibitor, ruxolitinib cream. In the early 1990s, various discovery and clinical development programs were initiated to explore pharmaceutical inhibition of the JAK-STAT pathway. Incyte Corporation launched a strategy to identify molecules suitable for both topical as well as oral delivery. Ruxolitinib was designed as a molecule with low nanomolar potency selective for JAK1 and 2 enzymes, but without significant inhibition of non-JAK kinases, as well as physicochemical properties for both topical and oral administration. An oil-in-water emulsified ruxolitinib cream formulation was developed for topical application and was studied in multiple immune-mediated dermatologic diseases including psoriasis, alopecia areata, atopic dermatitis and vitiligo. Ruxolitinib cream represents a novel, JAK1/2 selective therapy that can be delivered directly to the skin to treat a number of cytokine-driven, inflammatory dermatoses.

Indexed as

atopic dermatitisinflammationJanus kinasetopicalvitiligo

Identifiers

PMID34371735
PMCPMC8309120
OpenAlexW3179713661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.